Dr. Michael Tomblyn, MD

Dr. Tomblyn practices at Baptist Memorial Hospital-Memphis in Memphis, Tennessee, part of Baptist Memorial Health Care.

Dr. Tomblyn's NPI, 1083758544, was assigned on February 17, 2007. Dr. Tomblyn graduated from Rush Medical College in 2004. Dr. Tomblyn holds Tennessee license 62366.

Dr. Tomblyn's primary practice is Baptist Memorial Hospital-Memphis, at 6019 Walnut Grove Road, Memphis, TN 38120 in Shelby County. The practice phone is (901) 226-5000.

Dr. Tomblyn's primary practice is Baptist Memorial Hospital-Memphis in Memphis, Tennessee, part of Baptist Memorial Health Care. Dr. Tomblyn is also affiliated with Baptist Memorial Hospital-Tipton. The medical group on file is Baptist Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tomblyn practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Tomblyn's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Tomblyn is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Tomblyn's licenses on file in 7 states: Tennessee, Arkansas, Mississippi, Illinois, Florida, Kansas and Minnesota.

Dmand AI lists anal cancer radiation, bladder cancer radiation, bone cancer radiation, brain cancer radiation, breast cancer radiation, cancer radiation-upper GI, cervical cancer radiation and head & neck cancer radiation among the conditions Dr. Tomblyn treats.

CMS data shows 3,616 Medicare services from Dr. Tomblyn across 19 procedure codes in 2024, for 196 Medicare patients. Medicare paid $233,386 for them.

CMS counts 196 Medicare patients who saw Dr. Tomblyn in 2024. The largest group is 65 to 74, with 102 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tomblyn's median patient age at 74, with 55% women.

In 2024, Dr. Tomblyn wrote 23 Medicare Part D claims for 17 patients. 91% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $92 in total drug cost. In 2018, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Tomblyn for performance year 2024, reported as part of a group. Dr. Tomblyn accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Tomblyn, published from 2008 to 2018. 2014 was the busiest year, with 2. The most frequent topics are Hematopoietic Stem Cell Transplantation, Antineoplastic Agents and Radioimmunotherapy. Dr. Tomblyn has published most often in Bone Marrow Transplant. Dr. Tomblyn's most frequent co-authors are Thomas E. Witzig, MD, Kamran Ali Ahmed, MD and Kevin Scott Baker, MD.

Dmand AI links Dr. Tomblyn to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Brain Neoplasms, Lymphoma, Large B-Cell, Diffuse and Central Nervous System Neoplasms.

CMS Open Payments shows 21 general payments to Dr. Tomblyn from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $9,689.

Dr. Tomblyn graduated from Rush Medical College in 2004.

Dr. Tomblyn is in network with 18 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.